Peter M. Haggie

3.6k total citations · 1 hit paper
46 papers, 2.8k citations indexed

About

Peter M. Haggie is a scholar working on Pulmonary and Respiratory Medicine, Molecular Biology and Cell Biology. According to data from OpenAlex, Peter M. Haggie has authored 46 papers receiving a total of 2.8k indexed citations (citations by other indexed papers that have themselves been cited), including 26 papers in Pulmonary and Respiratory Medicine, 25 papers in Molecular Biology and 8 papers in Cell Biology. Recurrent topics in Peter M. Haggie's work include Cystic Fibrosis Research Advances (23 papers), Neonatal Respiratory Health Research (12 papers) and Ion Transport and Channel Regulation (8 papers). Peter M. Haggie is often cited by papers focused on Cystic Fibrosis Research Advances (23 papers), Neonatal Respiratory Health Research (12 papers) and Ion Transport and Channel Regulation (8 papers). Peter M. Haggie collaborates with scholars based in United States, United Kingdom and Canada. Peter M. Haggie's co-authors include A. S. Verkman, A.S. Verkman, Gergely L. Lukács, Luis J. V. Galietta, Neal D. Freedman, Olivier Seksek, Delphine Lechardeur, A. S. Verkman, Puay‐Wah Phuan and S. James Remington and has published in prestigious journals such as Journal of Biological Chemistry, Journal of Clinical Investigation and Journal of Neuroscience.

In The Last Decade

Peter M. Haggie

46 papers receiving 2.7k citations

Hit Papers

Size-dependent DNA Mobility in Cytoplasm and Nucleus 2000 2026 2008 2017 2000 100 200 300 400 500

Peers

Peter M. Haggie
Paul A. Negulescu United States
Margaret McLaughlin United States
Joachim Biwersi United States
I. R. Flockhart United Kingdom
Javier Farinas United States
Hua Tang United States
Yun Luo United States
Alan Boyd United Kingdom
Paul A. Negulescu United States
Peter M. Haggie
Citations per year, relative to Peter M. Haggie Peter M. Haggie (= 1×) peers Paul A. Negulescu

Countries citing papers authored by Peter M. Haggie

Since Specialization
Citations

This map shows the geographic impact of Peter M. Haggie's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Peter M. Haggie with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Peter M. Haggie more than expected).

Fields of papers citing papers by Peter M. Haggie

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Peter M. Haggie. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Peter M. Haggie. The network helps show where Peter M. Haggie may publish in the future.

Co-authorship network of co-authors of Peter M. Haggie

This figure shows the co-authorship network connecting the top 25 collaborators of Peter M. Haggie. A scholar is included among the top collaborators of Peter M. Haggie based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Peter M. Haggie. Peter M. Haggie is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Haggie, Peter M., et al.. (2024). High potency 3-carboxy-2-methylbenzofuran pendrin inhibitors as novel diuretics. European Journal of Medicinal Chemistry. 283. 117133–117133. 1 indexed citations
2.
Haggie, Peter M., et al.. (2023). Selective isoxazolopyrimidine PAT1 (SLC26A6) inhibitors for therapy of intestinal disorders. RSC Medicinal Chemistry. 14(11). 2342–2347. 2 indexed citations
3.
Çil, Onur, Marc O. Anderson, Lívia de Souza Gonçalves, et al.. (2023). Small molecule inhibitors of intestinal epithelial anion exchanger SLC26A3 (DRA) with a luminal, extracellular site of action. European Journal of Medicinal Chemistry. 249. 115149–115149. 9 indexed citations
5.
6.
Ortiz-Muñoz, Guadalupe, Michelle Yu, Emma Lefrançais, et al.. (2020). Cystic fibrosis transmembrane conductance regulator dysfunction in platelets drives lung hyperinflammation. Journal of Clinical Investigation. 130(4). 2041–2053. 39 indexed citations
7.
Krainer, Georg, Hideki Shishido, Jae Seok Yoon, et al.. (2020). Towards next generation therapies for cystic fibrosis: Folding, function and pharmacology of CFTR. Journal of Cystic Fibrosis. 19. S25–S32. 21 indexed citations
8.
Phuan, Puay‐Wah, Joseph‐Anthony Tan, Lorna Zlock, et al.. (2019). Nanomolar-potency ‘co-potentiator’ therapy for cystic fibrosis caused by a defined subset of minimal function CFTR mutants. Scientific Reports. 9(1). 17640–17640. 47 indexed citations
9.
Phuan, Puay‐Wah, Jung‐Ho Son, Joseph‐Anthony Tan, et al.. (2018). Combination potentiator (‘co-potentiator’) therapy for CF caused by CFTR mutants, including N1303K, that are poorly responsive to single potentiators. Journal of Cystic Fibrosis. 17(5). 595–606. 47 indexed citations
10.
Çil, Onur, Peter M. Haggie, Puay‐Wah Phuan, Joseph‐Anthony Tan, & A.S. Verkman. (2016). Small-Molecule Inhibitors of Pendrin Potentiate the Diuretic Action of Furosemide. Journal of the American Society of Nephrology. 27(12). 3706–3714. 36 indexed citations
11.
Valentine, Cathleen D., Marc O. Anderson, Feroz R. Papa, & Peter M. Haggie. (2013). X-Box Binding Protein 1 (XBP1s) Is a Critical Determinant of Pseudomonas aeruginosa Homoserine Lactone-Mediated Apoptosis. PLoS Pathogens. 9(8). e1003576–e1003576. 20 indexed citations
13.
Valentine, Cathleen D., A. S. Verkman, & Peter M. Haggie. (2011). Protein Trafficking Rates Assessed by Quantum Dot Quenching with Bromocresol Green. Traffic. 13(1). 25–29. 7 indexed citations
14.
Haggie, Peter M. & A. S. Verkman. (2007). Cystic Fibrosis Transmembrane Conductance Regulator-independent Phagosomal Acidification in Macrophages. Journal of Biological Chemistry. 282(43). 31422–31428. 98 indexed citations
15.
Haggie, Peter M., Jung Kyung Kim, Gergely L. Lukács, & A. S. Verkman. (2006). Tracking of Quantum Dot-labeled CFTR Shows Near Immobilization by C-Terminal PDZ Interactions. Molecular Biology of the Cell. 17(12). 4937–4945. 113 indexed citations
16.
Haggie, Peter M., Bruce A. Stanton, & A. S. Verkman. (2004). Increased Diffusional Mobility of CFTR at the Plasma Membrane after Deletion of Its C-terminal PDZ Binding Motif. Journal of Biological Chemistry. 279(7). 5494–5500. 71 indexed citations
17.
Binder, Devin K., Marios C. Papadopoulos, Peter M. Haggie, & A. S. Verkman. (2004). In VivoMeasurement of Brain Extracellular Space Diffusion by Cortical Surface Photobleaching. Journal of Neuroscience. 24(37). 8049–8056. 156 indexed citations
18.
Galietta, Luis J. V., Peter M. Haggie, & A. S. Verkman. (2001). Green fluorescent protein‐based halide indicators with improved chloride and iodide affinities. FEBS Letters. 499(3). 220–224. 298 indexed citations
19.
Jayaraman, Sujatha, Peter M. Haggie, Rebekka M. Wachter, S. James Remington, & A. S. Verkman. (2000). Mechanism and Cellular Applications of a Green Fluorescent Protein-based Halide Sensor. Journal of Biological Chemistry. 275(9). 6047–6050. 237 indexed citations
20.
Haggie, Peter M. & Kevin M. Brindle. (1999). Mitochondrial Citrate Synthase Is Immobilized in Vivo. Journal of Biological Chemistry. 274(7). 3941–3945. 29 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026